Mirum Pharmaceuticals Inc. (MIRM) is a biopharmaceutical company based in Foster City, California. Founded in 2018, it is focused on bringing innovative therapeutics to patients with underserved liver diseases. This diligent company is relatively young but has shown exceptional determination in tackling liver diseases that have often been neglected by medical science.
Mirum Pharmaceuticals honed in on devastating liver conditions like progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS), diseases that are often brutal and unpredictable, severely affecting the lives of their patients. Mirum's mission to develop therapies to overcome these uncommon but painful diseases has the potential to greatly improve the quality of life for affected patients.
The company emphasizes its commitment to scientific rigor, clinical excellence, and innovation. It has a robust pipeline of therapies in different stages of development and approval, all specialized towards helping those suffering from rare cholestatic liver diseases. Mirum Pharmaceuticals has developed a drug called maralixibat, a potential oral inhibitor which is in late-stage clinical development for treating pediatric diseases like ALGS and PFIC.
Mirum Pharmaceuticals, listed on NASDAQ as MIRM, has established itself as a dedicated force in the biopharmaceutical sector. Its focused efforts to target less common diseases has caught the attention of investors looking for companies striving to make an impact in the healthcare domain. Mirum has demonstrated their capacity to raise substantial funding, reflective of investor confidence in the company’s pipeline.
The company has built a strong team of pharmaceutical veterans who bring decades of experience to the table. Together, the team channels their expertise in drug development, clinical research, patient advocacy, and the healthcare industry into ways and means to help patients suffering from debilitating liver diseases.
Mirum Pharmaceuticals has shown an impressive dedication to combating under-recognized liver diseases. Its unwavering commitment to patients and breaking down barriers to advance healthcare is congruent with its vision to illuminate the path to improved health for patients who otherwise have limited treatment options.
In summary, Mirum Pharmaceuticals, Inc. (MIRM) is a distinctive biopharmaceutical company focused on developing and providing revamped therapeutics for patients with underserved liver diseases. Its mission, backed by strong investor confidence and substantial funding, has potential to transform the treatment paradigm for patients suffering from such diseases. This company is undoubtedly lighting up new paths in the realm of liver disease treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Mirum Pharmaceuticals has appointed Rob Myers, MD, as its new Chief Medical Officer. Dr. Myers brings over two decades of experience in developing novel medicines, particularly as a hepatologist, and will lead Mirum's global medical and clinical development functions. His appointment is expected to support the rare disease company's growing commercial portfolio and late-stage pipeline, replacing Joanne Quan, MD, who is departing the company.
This article provides a detailed stock analysis for Mirum Pharmaceuticals Inc. (NASDAQ: MIRM), indicating a neutral near and mid-term outlook with a potentially moderating long-term positive bias. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis, including support and resistance levels. The analysis highlights an elevated downside risk due to the absence of additional long-term support signals.
Mirum Pharmaceuticals Inc. has retained LMH Strategic Solutions LLC to represent its lobbying interests on Capitol Hill, specifically focusing on health policy. This engagement comes as Congress addresses the implications of the "One Big Beautiful Bill Act," which expanded orphan drug exemptions from Medicare price negotiation. Alanna Temme, founder of LMH Strategic Solutions, will lead the lobbying efforts for Mirum Pharmaceuticals.
Mirum Pharmaceuticals' SVP and Global Controller, Howe Jolanda, sold 658 shares of the company stock at $100 per share on September 2, 2026. After this transaction, Jolanda retains ownership of 616 shares of Mirum Pharmaceuticals (NASDAQ: MIRM). This insider sale provides insight into the executive's actions and remaining stake in the company for investors.
Mirum Pharmaceuticals CEO Christopher Peetz sold 30,000 shares of company stock for $2.96 million on September 1, 2026, following the exercise of stock options. The sales were conducted under a Rule 10b5-1 trading plan. Despite the company's strong revenue growth and positive analyst ratings, its stock is considered overvalued, and there are regulatory concerns regarding a key drug candidate.
_07_03_2026_03_50_21_133108.jpg)
Jolanda Howe, SVP and Global Controller at Mirum Pharmaceuticals (NASDAQ: MIRM), sold 658 shares of company stock on September 2, 2026, at $100 per share. This transaction was conducted under a pre-established Rule 10b5-1 trading plan. After the sale, Howe directly holds 616 shares of Mirum Pharmaceuticals.
Christopher Peetz, CEO of Mirum Pharmaceuticals (NASDAQ:MIRM), exercised a fully vested stock option for 30,000 shares and subsequently sold all these shares in two tranches on September 1, 2026. These transactions, executed under a Rule 10b5-1 trading plan, resulted in weighted average sale prices of $98.08 and $98.91 respectively. Post-transactions, Peetz directly holds 194,440 shares and indirectly 187,500 shares through The Peetz Family Trust, while retaining 58,487 employee stock options.